Entering text into the input field will update the search result below

Allergan's positive data on migraine prevention med atogepant pressures Alder Bio, down 4%

Jun. 11, 2018 12:25 PM ETAllergan plc (AGN) StockAGN, ALDRBy: Douglas W. House, SA News Editor
  • As is so often the case, good news for one biotech is bad for another. Allergan (AGN +1.1%) is in the green after reporting positive data on CGRP receptor antagonist atogepant for the prevention of migraine.
  • Alder Biopharmaceuticals (ALDR -3.5%) is in the red, albeit on below-average volume, as some investors react to the potential threat to lead candidate eptinezumab, a monoclonal antibody CGRP inhibitor in late-stage development for migraine prevention. A U.S. marketing application is on tap for early 2019.
  • Previously: Alder's eptinezumab shows treatment benefit in late-stage migraine study (April 24)

Recommended For You

More Trending News

Related Stocks

SymbolLast Price% Chg
AGN--
Allergan plc